A frontline chemotherapy-free strategy using a tyrosine kinase inhibitor and immunotherapy beats the conventional chemotherapy approach for treating Philadelphia-positive acute lymphoblastic leukaemia ...

Brentuximab vedotin (Adcetris, Takeda) is now on the PBS as part of the multi-drug BrECADD chemotherapy regimen for front-line treatment in adult patients with advanced stage CD30+ Hodgkin lymphoma.

JAK inhibitors should be an option for symptomatic myelofibrosis patients even if their disease is low risk, according to new guidelines from the American Society of Hematology (ASH). Published in ...

The addition of the bispecific T-cell engager tarlatamab to durvalumab as first-line maintenance therapy significantly improves survival in patients with extensive-stage small-cell lung cancer (SCLC).

SGLT2 inhibitor use in patients with cardiovascular disease, diabetes, heart failure, and/or chronic kidney disease is associated with small but statistically significant and consistent increases in ...

Trials of agents for the management of IgA nephropathy dominated the American Society of Nephrology’s 2026 Kidney Week, including three featured as high-impact trials in the opening plenary and four ...

PCOS is likely to need another rebrand in the near future because its new name, PMOS, is scientifically inaccurate, it is being argued. A debate over the future name of polycystic ovary syndrome has ...

Suspected paper mill papers in leading cancer journals are racking up far more citations than genuine articles, despite attracting fewer readers, according to an Australian-led forensic bibliometric ...

Young adults who had repeated courses of antibiotics from childhood onwards are more likely to have irritable bowel syndrome by age 24, with the odds rising as their antibiotic exposure increased, ...

The image of the wise and skilful healer has driven countless clinicians to dedicate their lives to the profession, but that ...

Watch again as an expert panel shares the latest clinical evidence on current treatment and management strategies for paroxysmal nocturnal haemoglobinuria, focusing on frontline and second-line care.